Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer by Agrelo, Ruben et al.
Epigenetic inactivation of the premature aging
Werner syndrome gene in human cancer
Ruben Agrelo*, Wen-Hsing Cheng†, Fernando Setien*, Santiago Ropero*, Jesus Espada*, Mario F. Fraga*,
Michel Herranz*, Maria F. Paz*, Montserrat Sanchez-Cespedes*, Maria Jesus Artiga*, David Guerrero‡,
Antoni Castells§, Cayetano von Kobbe*, Vilhelm A. Bohr†, and Manel Esteller*¶
*Cancer Epigenetics Laboratory, Spanish National Cancer Centre, Melchor Fernandez Almagro 3, 28029 Madrid, Spain; †Laboratory of Molecular
Gerontology, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224; ‡Centro de Investigación
Biomédica, Servicio Navarro de Salud, 31008 Pamplona, Navarra, Spain; and §Department of Gastroenterology, Hospital Clinic, Institut d’Investigacions
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Werner syndrome (WS) is an inherited disorder characterized by
premature onset of aging, genomic instability, and increased
cancer incidence. The disease is caused by loss of function muta-
tions of the WRN gene, a RecQ family member with both helicase
and exonuclease activities. However, despite its putative tumor-
suppressor function, little is known about the contribution of WRN
to human sporadic malignancies. Here, we report that WRN func-
tion is abrogated in human cancer cells by transcriptional silencing
associated with CpG island-promoter hypermethylation. We also
show that, at the biochemical and cellular levels, the epigenetic
inactivation of WRN leads to the loss of WRN-associated exonu-
clease activity and increased chromosomal instability and apopto-
sis induced by topoisomerase inhibitors. The described phenotype
is reversed by the use of a DNA-demethylating agent or by the
reintroduction of WRN into cancer cells displaying methylation-
dependent silencing of WRN. Furthermore, the restoration of WRN
expression induces tumor-suppressor-like features, such as re-
duced colony formation density and inhibition of tumor growth in
nude mouse xenograft models. Screening a large collection of
human primary tumors (n  630) from different cell types revealed
that WRN CpG island hypermethylation was a common event in
epithelial and mesenchymal tumorigenesis. Most importantly,
WRN hypermethylation in colorectal tumors was a predictor of
good clinical response to the camptothecin analogue irinotecan, a
topoisomerase inhibitor commonly used in the clinical setting for
the treatment of this tumor type. These findings highlight the
importance of WRN epigenetic inactivation in human cancer, lead-
ing to enhanced chromosomal instability and hypersensitivity to
chemotherapeutic drugs.
DNA methylation
Werner syndrome (WS) is an autosomal recessive diseasecharacterized by premature aging and a high incidence of
malignant neoplasms (1, 2). Mutations in the WS gene (WRN) are
found in patients exhibiting the clinical symptoms of WS (3–5). The
vast majority of WRN mutations result in loss of function of the
WRN protein (6). The WRN protein has been demonstrated to
possess helicase and exonuclease activities (7–9), and cultures of
WS cells show increased chromosomal instability, with abundant
deletions, reciprocal translocations, and inversions (10, 11).
WRN belong to the RecQ family of helicases, which are highly
conserved from bacteria to human, and whose members are
thought to be essential caretakers of the genome (11, 12). In
addition to WRN, germline mutations of two other RecQ helicases,
BLM in Bloom syndrome and RECQL4 in Rothmund–Thomson
syndrome, are also associated with an elevated incidence of cancer
(12). Because patients with WRN germline mutations develop a
broad spectrum of epithelial and mesenchymal tumors, which is one
of the main causes of their death before the age of 50, a tumor-
suppressor function for WRN has been proposed. This putative role
is also supported by a very high rate of loss of heterozygosity at the
chromosomal WRN loci at 8p11.2–p12 in many tumor types,
including colorectal and breast cancer (13, 14). However, somatic
mutations of WRN have not been described in sporadic neoplasms.
Transcriptional inactivation by CpG island promoter hypermeth-
ylation is an alternative and emergent mechanism for the inactiva-
tion of tumor-suppressor genes (15–18). Similar scenarios to that
outlined for WRN have been described for other DNA-repair
familial-tumor-suppressor genes, such as hMLH1 and BRCA1,
which are very rarely mutated in sporadic tumors but undergo
epigenetic inactivation by hypermethylation of their regulatory
regions in noninherited neoplasms (15, 17, 19, 20).
In this manuscript, we demonstrate that WRN undergoes CpG
island promoter methylation-associated gene silencing in human
cancer cells. The hypermethylation of the WRN promoter leads to
its loss of expression and hypersensitivity to topoisomerase inhib-
itors and DNA-damaging agents. The epigenetic loss of WRN
function can be rescued by the use of DNA-demethylating agents.
Furthermore, the reintroduction of WRN into those transformed
cell lines with WRN-deficiency due to hypermethylation provokes
a reduction in colony formation and a decrease in growth of tumor
xenografts, supporting the hypothesis that WRN has a tumor-
suppressor role. The analysis of a large panel of human primary
tumors (n  630) shows that WRN CpG island hypermethylation
is a common event in tumorigenesis. Most importantly, for colo-
rectal cancer, the presence of aberrant methylation at the WRN
promoter predicts improved survival in those patients treated with
irinotecan, a topoisomerase inhibitor commonly used in this neo-
plasm. These findings underline the significance of WRN as a
caretaker of our genome with tumor-suppressor activity and iden-
tify epigenetic silencing of WRN as a key step in cancer develop-
ment that may have an important clinical influence on the treat-
ment of these patients.
Results
WRN Promoter CpG Island Hypermethylation Leads to Gene Inactiva-
tion. WRN is a gene candidate for hypermethylation-associated
inactivation in human cancer because a 5-CpG island is located
around the transcription start site (Fig. 1A). To analyze the meth-
ylation status of the promoter-associated CpG island, we screened
seven human cancer cell lines from three different cell types of
malignancies, colon (HCT-116 and COLO-205), breast (MCF-7
and MDA-MB-231), and leukemia (HL-60, U937, and REH), using
bisulfite genomic sequencing and methylation-specific PCR tar-
geted to the area surrounding the transcription start site, as
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described in Methods. WRN CpG island promoter hypermethyl-
ation was found in four cancer cell lines: HCT-116, COLO-205,
MDA-MB-231, and U937 (Figs. 1 A and B). All normal tissues
analyzed, including lymphocytes, bone marrow, breast, colon, and
skin, were completely unmethylated at the WRN promoter
(Fig. 1A).
Having noted WRN promoter hypermethylation in cancer cell
lines, we assessed the association between this epigenetic aberration
and the putative transcriptional inactivation of the WRN gene at
the RNA and protein levels. The cancer cell lines HCT-116,
COLO-205, MDA-MB-231, and U937 hypermethylated at the
WRN CpG island did not express (HCT-116, COLO-205, and
U937) or had minimal expression of (MDA-MB-231) the WRN
RNA transcript, as determined by RT-PCR (Fig. 1C) and WRN
protein, as determined by Western blot (Fig. 1C) and immuno-
fluorescence (Fig. 1E). In contrast, MCF-7, HL-60, and REH,
unmethylated at the WRN promoter, expressed WRN protein
(Fig. 1 C–E).
We established a further link between WRN CpG island hyper-
methylation and its gene silencing by the treatment of the methyl-
ated cell lines with a DNA-demethylating agent. The treatment of
the HCT-116, COLO-205, MDA-MB-231, and U937 cell lines with
the demethylating drug 5-aza-2-deoxycytidine restored the expres-
sion of WRN RNA transcript and protein (Fig. 1 C–E). It is not only
a matter of restoring gene expression but also of rescuing gene
functionality. This is exemplified by several genes that undergo
methylation-associated silencing, such as the DNA-repair gene
hMLH1, the MDM2-regulator p14ARF, or the glycosyltransferase
EXT-1, where treatment with the demethylating agent induced
recovery of gene functions: DNA mismatch repair activity, seques-
tration of MDM2, and heparan sulfate biosynthesis, respectively
(19, 21, 22). Because WRN is the only RecQ member that exhibits
exonuclease activity (9), we examined the impact of WRN meth-
ylation-mediated silencing in this enzymatic function of WRN and
the effect of restoring WRN expression by pharmacological means.
We observed a loss of exonuclease enzymatic activity in WRN-
immunoprecipitated cell extracts of U937 and MDA-MB-231, all of
them hypermethylated at the WRN promoter, compared with
HL60 and MCF-7 cells, these latter two having an unmethylated
WRN promoter (Fig. 1F). Most important, treatment of U937 cells
with the demethylating agent 5-aza-2-deoxycytidine induced a
significant increase in the WRN-associated exonuclease activity in
these cells (Fig. 1F).
Reintroduction of WRN in Hypermethylation-Deficient Cancer Cell
Lines Has Tumor-Suppressor-Like Properties. Although it has been
proposed before that WRN has tumor-suppressor gene features, we
assayed the ability of WRN to function as a suppressor of tumor
growth in our model, using the breast cancer cell line MDA-MB-
231 with WRN methylation-associated silencing. We first tested the
inhibitory abilities of WRN in a colony-focus assay using G418
selection after transfection with the WRN gene (pEGFP-C1-
Fig. 1. Analysis of WRN CpG island promoter methylation status and gene function in human cancer cell lines. (A) Schematic depiction of the WRN CpG island
around the transcription start site (long black arrow). CpG dinucleotides are represented as short vertical lines. Location of bisulfite genomic sequencing PCR
primers and methylation-specific PCR primers are indicated as white and gray arrows, respectively. Shown are results of bisulfite genomic sequencing of 12
individual clones. Presence of a methylated or unmethylated cytosine is indicated by a black or white square, respectively. (B) Methylation-specific PCR for the
WRN gene in human cancer cell lines. The presence of a PCR band under lanes M or U indicates methylated or unmethylated genes, respectively. In vitro
methylated DNA (IVD) is used as positive control for methylated DNA. (C) RT-PCR analysis of WRN expression. Treatment with the demethylating agent (ADC 
lanes) reactivates WRN gene expression. (D) Western blot analysis of WRN expression. The WRN hypermethylated cell lines HCT-116, MDA-MB-231, and U937
do not express the WRN protein or have minimal expression (MDA-MB-231). The treatment with the demethylating agent reactivates WRN gene expression.
WS cells are shown as negative control. (E) Immunofluorescence analysis of WRN expression. The methylated cell lines COLO-205 and U937 and the mutant
WS cells do not stain for the WRN protein, in comparison with the unmethylated MCF-7 cells. Treatment with the demethylating agent (DAC) restores protein
expression. (F) Exonuclease activity assay in WRN-immunoprecipitated cell resolved on denaturing polyacrylamide gels. The 3-recessed duplex substrate used
for exonuclease studies was degraded more extensively in WRN unmethylated cells (MCF-7 and HL60) than in WRN methylated (U937 and MDA-MB-231) or
mutated (WRN) cells.











WRN) or the empty vector (pEGFP-C1). WRN expression was
monitored by RT-PCR (Fig. 2A). Inhibition of tumor-cell growth
was assessed by seeding MDA-MB-231-transfected cells on meth-
ylcellulose, incubating for 15 days, and then scoring the number of
colonies formed. WRN re-expression demonstrated tumor-
suppressing activity with a marked reduction of 59  10% in
colony-formation density with respect to the empty vector
(Fig. 2A).
We next tested the ability of WRN-transfected MDA-MB-231
cells to form tumors in nude mice compared with that of
empty-vector-transfected MDA-MB-231 cells. The same mice
were s.c. injected with 106 WRN or empty-vector-transfected
MDA-MB-231 cells (Fig. 2B). All mice were killed 30 days after
the injection, and the tumors were dissected and weighed. Cells
transfected with the empty vector (MDA-MB-231pEGFP-C1)
formed tumors rapidly, but cells infected with the WRN expres-
sion vector (MDA-MB-231pEGFP-C1-WRN) had much lower
tumorigenicity (Fig. 2B). At the time of death, tumors were six
times larger in those mice with the empty vector, 500  167.3 mg,
than in those xenografts arising in mice transfected with WRN,
86  50.4 mg (Fig. 2B).
Hypermethylation-Deficient WRN Cancer Cells Are Sensitive to Inhib-
itors of Topoisomerase I and DNA-Damaging Agents. It is already well
known that lymphoblastoid cells and fibroblasts established from
WS patients (11, 23–26) and embryonic stem cells from WRN-
deficient mice (27) are hypersensitive to chromosomal damage and
apoptosis upon their exposure to topoisomerase inhibitors and
DNA cross-linking drugs. Related to the mechanism of apoptosis
upon exposure to topoisomerase inhibitors, it has been associated
with the persistence of a topoisomerase I–DNA intermediate in
WRN cells from WRN patients that it generates stalled
replication forks (28). It would be extremely interesting to know, for
clinical translational purposes, whether cancer cells with WRN-
methylation-associated silencing also display these functional fea-
tures. To address this issue, we treated WRN-unmethylated and
hypermethylated cancer cell lines with camptothecin (a topoisom-
erase I inhibitor) or mitomycin C (an interstrand crosslinker) and
measured the apoptotic rate by flow cytometry and chromosomal
breakage by cytogenetic analysis.
For the apoptosis study, we observed that both camptothecin and
mitomycin C were optimal inductors of apoptosis in the breast
cancer cell line MDA-MB-231 and the leukemia cell line U937 (Fig.
3A; and see Fig. 5, which is published as supporting information on
the PNAS web site), both of which display WRN promoter hyper-
methylation. The same phenomenon was observed for the cell line
from a WS patient used as a positive control (Fig. 3A). By striking
contrast, the breast cancer cell line MCF-7, unmethylated at the
WRN promoter, was markedly resistant to camptothecin and
mitomycin C-induced apoptosis (Fig. 3A). Most importantly, when
we used WRN-transfected U937 and MDA-MB-231 cells, the
resulting cells became more resistant to the apoptosis mediated by
both drugs (Figs. 3A and 5).
The results of the chromosomal breakage analysis reflect those
obtained from the apoptotic assays. Human cancer cell lines with
an unmethylated WRN promoter, such as the breast cancer MCF-7
or the leukemic HL60 cells, demonstrated minimal chromosomal
breakage upon exposure to mitomycin (Fig. 3B). In contrast, both
cells from a WS patient and the breast MDA-MB-231 cells with
WRN aberrant methylation were extremely sensitive to the drug,
and a high frequency of chromosomal breakages, sometimes even
in the characteristic form of quatriradial chromosomes, were ob-
served in metaphases (Fig. 3B). Furthermore, when WRN-
transfected MDA-MB-231 cells were exposed to mitomycin C, they
acquired resistance to chromosomal breakage (Fig. 3B). Finally, the
down-regulation of WRN by RNA interference in cells with an
unmethylated promoter (MCF-7) was associated with an increased
ratio of chromosomal breakage upon exposure to mitomycin C (Fig.
3C). All of these results establish a tight link between loss of WRN
and increased sensitivity to the chemotherapeutic drug.
Profile of WRN CpG Island Hypermethylation in Human Primary
Malignancies. After the demonstration of the epigenetic loss of
function of WRN in cancer cell lines, we assessed the prevalence of
WRN CpG island promoter hypermethylation in cancer patients.
We examined 630 primary tumors corresponding to 11 different
tissue types. WRN CpG island promoter hypermethylation was
observed at different frequencies in each class of neoplasm and was
present in epithelial and mesenchymal tumors (Fig. 4A). WRN
hypermethylation of epithelial tumors was most prevalent in colo-
rectal cancer (37.9%, 69182), followed by non-small cell lung
(37.5%, 2156), gastric (25%, 1038), prostate (20%, 420), breast
(17.2%, 1058), and thyroid (12.5%, 432) tumors. Of the hema-
tological malignancies, promoter methylation of the WRN gene was
often found in non-Hodgkin lymphoma (23.7%, 28118) but was
much less common in acute lymphoblastic leukemia (9.5%, 221)
and acute myeloblastic leukemia (4.8%, 363). For the mesenchy-
mal tumor types, WRN hypermethylation was present in chondro-
sarcomas (33.3%, 515) and osteosarcomas (11.1%, 327).
To further confirm the correlation between WRN hypermeth-
Fig. 2. Tumor-suppressor-like properties of WRN reintroduction. (A) Colony-
formation assay. (Upper Left) WRN expression monitored by RT-PCR in un-
transfected and WRN-transfected MDA-MB-231 cells monitored by RT-PCR.
(Lower Left) Densitometric quantification of the colony formation density of
MDA-MB-231 cells transfected with the empty vector or with WRN. Three
independent experiments were carried out. (Right) Example of the colony
focus assay after a 2-week selection with G418 and staining with methylene
blue. (B) Effect of WRN transfection on the in vivo growth of MDA-MB-231
cells. Tumor weight and size was monitored over time. Shown are female
athymic nude mice 30 days after injection of 106 MDA-MB-231 cells. Note the
large tumor on the left flank, corresponding to empty vector MDA-MB-231
cells, and the small tumor on the opposite flank, corresponding to WRN-MDA-
MB-231 cell injection.
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ylation and loss of WRN protein also in primary tumors, we
conducted a double-blind analysis in primary gastric and colorectal
tumors. For 16 cases of gastric tumors, an immunohistochemistry
study of the WRN protein was carried out. In all cases with an
unmethylated WRN promoter (n  8) the WRN protein was
strongly expressed; in contrast, the 8 methylated cases lacked WRN
expression (Fig. 4B). We also analyzed 16 cases of colorectal tumors
using WRN Western blotting. We found again that all of the
unmethylated cases (n  8) expressed the WRN protein, whereas
for the methylated cases (n  8), 7 (87%) lacked WRN expression
and only 1 remaining case retained minimal expression of the WRN
protein (Fig. 4B).
WRN Hypermethylation in Colon Cancer Patients Predicts Good Re-
sponse to the Camptothecin Analogue Irinotecan. Because cell lines
from WS patients are extremely sensitive to the drug campto-
thecin (11, 23–26), and given our finding, above, that human
cancer cells with WRN-methylation-associated silencing are also
very sensitive to this drug, we wondered whether these obser-
vations could also be translated to clinical samples. In this
context, one camptothecin analogue, irinotecan (CPT-11), has
been approved for clinical use in the treatment of colon cancer,
a tumor type in which we found a significant rate of WRN CpG
island hypermethylation.
We therefore assessed whether the presence of WRN pro-
moter hypermethylation was a predictive marker of response to
irinotecan in colorectal cancer patients treated with this drug.
We selected a similar number of WRN-hypermethylated (n 
45) and unmethylated (n  43) primary colorectal tumors from
patients treated with irinotecan for whom a long clinical fol-
low-up was available. We found that the median time for death
of patients was 39.4 months for WRN methylated colon tumors
but only 20.7 months for WRN unmethylated colon tumors.
Thus, the presence of WRN CpG island promoter hypermeth-
ylation was a significant predictor of increased overall survival in
colon cancer patients treated with irinotecan (Kaplan–Meier,
P  0.00005; 95% confidence interval, 25.4–35.2) (Fig. 4C).
Discussion
Aging is the main risk factor associated with cancer development
(29). Thus, it makes sense that the inactivation of a gene involved
in ‘‘preventing’’ the aging process occurs in cancer cells. We
recently found the first example of this concept: lamin AC
(LMNA) is mutated in atypical WS, where the WRN gene is wild
type (30), whereas LMNA undergoes methylation-associated
silencing in hematological neoplasms (31). Here, we demon-
strate that the first and paradigmatic premature aging gene,
WRN, undergoes epigenetic inactivation in human cancer and
can be viewed as a tumor-suppressor gene.
Patients with WS display a remarkable number of clinical signs
and symptoms associated with premature aging, including gray-
ing of the hair, cataracts, osteoporosis, diabetes, and atheroscle-
Fig. 3. Hypermethylation-deficient WRN
cancer cells are sensitive to inhibitors of
topoisomerase I and DNA-damaging
agents. (A) Induction of apoptosis mea-
sured by flow cytometry in unmethylated
(MCF-7), methylated (MDA-MB-231), and
mutated (WS) WRN cells at increasing
concentrations of camptothecin and mito-
mycin C. MDA-MB-231 and WS cells are
highly sensitive in comparison with MCF-7.
Restoration of WRN expression in MDA-
MB-231 cells induces resistance to apopto-
sis by both drugs. (B) Chromosomal break-
age measured by cytogenetic analysis of
metaphase chromosomes. (Upper Left) Un-
treated MDA-MB-231 cells have undetect-
able fragility. (Upper Right) 50 mgml mit-
omycin C-treated cells undergo a massive
breakage (empty vector). (Lower Left)
MDA-MB-231 cells transfected with the
WRN gene display resistance to the ge-
nome damage. (Lower Right) Quantifica-
tion of chromosomal breakage induced by
mitomycin C in cells proficient (HL60 and
MCF-7) or deficient in WRN function by
mutation (WS) or methylation (MDA-
MB-231). Transfection of the WRN gene in
MDA-MB-231 cells provokes resistance to
the genomic damage induced by the drug.
(C) siRNA assay for the WRN transcript in
MCF-7 cells. (Right) Western blot of WRN-
knocked-down MCF-7 cells by siRNA. (Left)
Quantification of chromosomal breakage
induced by mitomycin C in MCF-7 proficient
cells or cells deficient in WRN function by
siRNA. WRN-knocked-down MCF-7 cells are
prone to chromosomal breakage upon ex-
posure to mitomycin C.











rosis starting as early as the second or third decade of life (1, 2).
Most important, WS patients have a high incidence of malignant
neoplasms (1, 2). What makes the case even more interesting it
is that the tumor type of neoplasms appearing in WS patients is
remarkably different from that observed in people who do not
have the syndrome: the ratio of mesenchymal:epithelial cancers
is 1:1, as compared with 1:10 in the normal aging population (12,
32). Thus, it seems that the accelerated aging process in WS
patients contributes to the higher incidence of tumors, but the
specific loss of the WRN gene confers a particular tumor-type
prone phenotype, in a similar fashion to what has been observed
with other familial tumor-suppressor genes with DNA-repair
function, such as hMLH1 or BRCA1 (33). Our observation that
the WRN gene undergoes epigenetic inactivation by CpG island
promoter hypermethylation in various tumor types of both
mesenchymal and epithelial origin, including those commonly
observed in WRN patients (such as osteosarcoma, thyroid, and
gastric tumors) (34), may provide further insight into the WRN
protein’s contribution to the tumorigenic process.
Several new avenues of research now present themselves, such as
the links between WRN epigenetic silencing and two critical
components of the cellular machinery, telomeres and p53. In the
first case, it is known that the WRN protein interacts with several
telomere proteins and unwinds a telomeric D-loop structure (35).
Furthermore, the loss of WRN function facilitates the activation of
the alternative lengthening of telomeres mechanism, which may
engender cancer-relevant chromosomal aberrations and tumor
formation in mouse models (36). Interestingly, alternative length-
ening of telomeres is commonly observed in sarcomas, where we
have also observed WRN hypermethylation and which are char-
acteristic of patients with WS. Similar questions can be applied to
p53. The induction of apoptosis by p53 is attenuated in WRN-
deficient cells (37), and this phenotype cannot be rescued by other
RecQ DNA helicases, such as BLM (38). Related to this last issue,
it is important to remember that WRN is the only RecQ DNA
helicase that, in addition to its helicase activity, has an exonuclease
activity (9). Thus, our exonuclease enzymatic determination in
WRN-immunoprecipitated cells provides a specific functional assay
for the WRN protein against all of the other RecQ DNA helicase
family members.
Finally, it is worth emphasizing the potential clinical relevance of
our findings. Our observations demonstrate that WRN hypermeth-
ylation renders these cancer cells very sensitive to the action of
inhibitors of topoisomerase and DNA-damaging agents. This is not
an observation merely restricted to laboratory models but one that
can be translated to real patients. We have shown that the use of a
chemotherapeutic agent with topoisomerase-inhibition activity, iri-
notecan, is associated with increased overall survival in colorectal
patients who display WRN promoter CpG island hypermethylation.
Larger prospective studies would be necessary to build on these
findings, but it is a line of translational research that merits further
exploration.
In summary, our results suggest that the abolition of the
tumor-suppressor functions of the progeroid WRN gene by
epigenetic silencing is a relevant event in human tumorigenesis,
associated with the generation of chromosomal instability. At
the same time, it constitutes an Achilles’ heel for these tumors,
because they become more sensitive to the chemotherapeutic
action of topoisomerase inhibitors and DNA-damaging agents.
All of these findings together represent another chapter in the
story of the close and long established connection between the
processes of aging and cancer.
Methods
Cell Lines and Tumor Samples. The 11 human cancer cell lines
examined in this study were obtained from the American Type
Culture Collection. The cell lines represented three different types
of malignancies, colon (HCT-116 and COLO-205), breast (MCF-7
and MDA-MB-231), and leukemia (HL-60, U937, and REH). Cell
lines were maintained in appropriate media and treated with 1 M
5-aza-2-deoxycytidine (Sigma) for 3 days to achieve demethylation
(19, 21, 22). WS  cells (AG11395) were obtained from the
Coriell Cell Repositories (Camden, NJ). The collection of primary
tumor samples analyzed is described in ref. 22.
DNA Methylation Analysis of the WRN Gene. We established WRN
CpG island methylation status by PCR analysis of bisulfite-modified
genomic DNA. First, methylation status was analyzed by bisulfite
genomic sequencing of both strands of the CpG island. The primers
used were 5-AGG TTT TTA GTY GGY GGG TAT TTA-3
(sense) and 5-AAC CCC CTC TTC CCC TCA-3 (antisense),
located at 209 bp and 164 bp from the transcription start site.
The second analysis used methylation-specific PCR with primers
specific for either the methylated or modified unmethylated DNA.
Primer sequences for the unmethylated reaction were 5-GTA GTT
GGG TAG GGG TAT TGT TTG T-3 (sense) and 5-AAA CAA
AAT CCA CCA CCC ACC CC-3 (antisense), and for the meth-
Fig. 4. WRN CpG island hypermethylation in primary human malignancies.
(A) Analysis of WRN methylation by methylation-specific PCR. The presence of
a PCR band under lane M indicates methylated genes. Normal lymphocytes
(NL) and in vitro methylated DNA (IVD) are used as negative and positive
control for unmethylated and methylated genes, respectively. (B) WRN pro-
tein expression in primary human tumors. (Upper) Immunohistochemistry of
WRN in a normal gastric gland (Left), unmethylated at WRN, and in an
unmethylated gastric tumor showing strong WRN expression (Center) and a
methylated gastric tumor demonstrating loss of WRN staining (Right). (Lower)
Western blot analyses of colorectal tumors showing the tight association
between WRN methylation and loss of expression. (C) Kaplan–Meier analysis
of WRN promoter hypermethylation in patients with colorectal cancer treated
with irinotecan and its impact on survival. A significant increased overall
survival is observed in patients with WRN methylation.
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ylated reaction were 5-CGG GTA GGG GTA TCG TTC GC-3
(sense) and 5-AAC GAA ATC CAC CGC CCG CC-3 (anti-
sense). Primers were located at 36 (sense) and 129 (antisense)
from the transcription start site.
WRN RNA and Protein Analysis by Western Blotting, Immunofluores-
cence, and Immunohistochemistry. RNA was isolated by using
TRIzol (Life Technologies). Two micrograms of RNA were re-
verse-transcribed by using SuperScript II reverse transcriptase
(GibcoBRL) and amplified by using specific primers for WRN
(forward, 5-GCA TGT GTT CGG AAG AGT GTT T-3; reverse,
5-TGA CAT GGA AGA AAC GTG GAA-3). PCR was per-
formed for 25 cycles (94°C for 30 s, 57°C for 30 s, and 72°C for 30 s).
Cell lysates for protein analysis were prepared and analyzed by
Western blotting with the WRN antibody ab200 (rabbit polyclonal;
Abcam). Immunofluorescence and immunohistochemistry exper-
iments were developed as described in refs. 22 and 30.
Exonuclease Assay. Exonuclease enzymatic activity was measured
as described in ref. 39, using lysates from 80,000 cells immunopre-
cipitated with WRN antibody H-300 (rabbit IgG; Santa Cruz
Biotechnology). The DNA exonuclease substrate consisted of a
double-stranded DNA molecule with one blunt end and one
recessed 3 end (5 overhang of 20 nucleotides). Reactions were
incubated at 37°C for 60 min. The digestion products of these
reactions were separated on 15% denaturing polyacrylamide gels
and visualized by using a PhosphorImager (Molecular Dynamics).
Flow Cytometry and Cytogenetic Assays. The percentage of apo-
ptotic cells was determined by flow cytometry using the Vybrant
apoptosis assay kit #4 (YO-PRO-1propidium iodide; Molec-
ular ProbesInvitrogen). Briefly, cells were washed twice with
ice-cold PBS and resuspended in PBS containing YO-PRO-1
propidium iodide. Apoptotic cells were identified by flow cy-
tometry after incubation for 20 min. For the cytogenetic assay,
100 metaphases were analyzed for each experimental condition.
WRN Transfection and Small Interfering RNA (siRNA) Assay. The
WRN coding sequence corresponding to the cDNA from a
B-LCL lymphoblastoid-EBV immortalized cell line was ampli-
fied by PCR and directly cloned into the pGEM-T Easy Vector
(Promega). The WRN insert was subcloned into the pEGFP-C1
expression vector (Invitrogen) and confirmed by sequencing. For
transfection experiments, we used the pEGFP-C1 vector con-
taining the WRN gene or the pEGFP-C1 empty vector. Trans-
fection of MDA-MB-231 and U937 cells was performed by
electroporating 107 cells. Electroporated cells were washed with
PBS and seeded with 106 cells per ml in fresh medium containing
20% FBS. Transfected cells were selected by the addition of
G418 (600 gml). The WRN interference assays were devel-
oped by using a siRNA duplex against the WRN gene that
recognizes the sequence 5-CAG GTG AAC TTA GGA AAC
TTA-3 (Qiagen). We used Scramble siRNA (Qiagen) as a
negative control.
Colony-Formation Assay. Colony formation on methylcellulose me-
dium (StemCell Technologies) was assayed. Transfected cells
were added to a medium containing 80% methylcellulose and
20% conditioned medium from MDA-MB-231 cultures and 600
gml G418. The mixture was then placed in a six-well plate and
incubated for 15 days. Colonies containing more than 20 cells
were scored as positive.
Mouse Xenograft Model. Six-week-old female athymic nude mice
nunu (Harlan Sprague Dawley, Indianapolis) were used for MDA-
MB-231 tumor xenografts. Ten specimen were used. Both flanks of
each animal were injected s.c. with 107 cells in a total volume of 200
l of PBS. The right flank was always used for WRN-MDA-MB-
231-transfected cells and the left for empty-vector MDA-MB-231
control cells. Tumor development at the site of injection was
measured daily.
Statistical Analysis. Contingency tables were analyzed by using
Fisher’s exact test. Overall survival curves were estimated by using
the Kaplan–Meier method and were compared with the log-rank
test. All statistical analyses were performed by using SPSS (Version
10.1; SPSS, Chicago).
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